KGLOW vs SS-31
KGLOW and SS-31 are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: KGLOW is four-component dermal research blend — ghk-cu 50 mg / bpc-157 10 mg / tb-500 10 mg / kpv 10 mg (80 mg total), while SS-31 is mitochondria-targeting aromatic-cationic tetrapeptide (cardiolipin-binding) — different molecular classes with different handling consequences; their leading degradation routes differ (copper dissociation from the ghk-cu component at acidic ph or on chelator contact for KGLOW, adsorptive loss to plasticware from the cationic charge for SS-31), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
KGLOW — origin
KGLOW is GLOW with a fourth component added: KPV, a tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. The other three amounts are unchanged — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg — with KPV at 10 mg bringing the vial to 80 mg. KPV is studied primarily for anti-inflammatory activity in preclinical models, notably retaining that property of the parent hormone without its pigmentation-related effects.
SS-31 — origin
SS-31 (Elamipretide) is a Szeto-Schiller aromatic-cationic tetrapeptide (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane and binds cardiolipin, the lipid unique to that membrane. Its structure is the reason it is studied specifically at the mitochondrion rather than as a general antioxidant.
KGLOW research themes
The majority component, with the deepest dermal research literature.
The addition that distinguishes KGLOW — studied for anti-inflammatory activity derived from alpha-MSH without pigmentation effects.
Two complementary tissue-repair mechanisms, unchanged from GLOW.
Adds an inflammation arm to the three repair-focused mechanisms in GLOW.
SS-31 research themes
Studied for selective association with cardiolipin in the inner mitochondrial membrane, the basis of its mitochondrial targeting.
Examined for effects on mitochondrial energy production in research models of mitochondrial dysfunction.
Investigated around reactive-oxygen-species handling at the mitochondrion.
KGLOW handling
- Never reconstitute in acidic diluent — copper dissociation from the GHK-Cu component is the primary risk.
- Keep EDTA and other chelators out of any buffer used with KGLOW.
- Treat colour as data: clear even blue is correct; pale or green is not.
- Protect from light and minimise headspace exposure for the TB-500 component.
- Scale diluent to the 80 mg fill — habitually adding 2 mL as though to a 10 mg vial gives a solution eight times more concentrated than intended.
SS-31 handling
- Reach room temperature before opening.
- Use low-bind labware and buffers at low working concentrations to limit adsorption of the cationic peptide.
- Aliquot and refrigerate.
Both third-party tested
Every Popular Peptides batch of KGLOW and SS-31 is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
KGLOW reference
Related comparisons
KGLOW and SS-31 are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.